- 米国企業
- EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc.EYPT
| 2012年 6月30日 | 2013年 6月30日 | 2014年 6月30日 | 2015年 6月30日 | 2016年 6月30日 | 2017年 6月30日 | 2018年 6月30日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 |
---|
Cash and cash equivalents | 5 | 7 | 15 | 19 | 15 | 17 | 39 | 22 | 45 | 179 | 96 |
---|
Marketable securities | 10 | 3 | 3 | 9 | 14 | - | - | - | - | 33 | 49 |
---|
Accounts and other receivables, net | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 11 | 9 | 18 | 16 |
---|
Prepaid expenses and other current assets | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 6 | 3 | 4 | 10 |
---|
Inventory | - | - | - | - | - | - | - | 2 | 5 | 4 | 3 |
---|
Total current assets | 16 | 12 | 19 | 30 | 30 | 18 | 40 | 42 | 63 | 238 | 173 |
---|
Property and equipment, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
---|
Operating lease right-of-use assets | - | - | - | - | - | - | - | 3 | 3 | 2 | 6 |
---|
Intangible assets, net | 4 | 3 | 3 | 2 | 1 | 0 | 31 | 28 | 25 | 23 | - |
---|
Restricted cash | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
---|
Total assets | 21 | 16 | 23 | 32 | 32 | 19 | 72 | 73 | 92 | 263 | 180 |
---|
Accounts payable | 0 | 1 | 0 | 1 | 1 | 1 | 3 | 4 | 5 | 7 | 6 |
---|
Accrued expenses | 1 | 2 | 2 | 3 | 4 | 4 | 4 | 7 | 8 | 14 | 16 |
---|
Deferred revenue | 2 | 1 | 0 | 0 | 0 | 0 | - | 0 | 1 | 1 | 1 |
---|
Short-Term Debt | - | - | - | - | - | - | - | - | - | - | 10 |
---|
Other current liabilities | - | - | - | - | - | - | - | - | 1 | 1 | 1 |
---|
Total current liabilities | 3 | 3 | 2 | 3 | 5 | 5 | 22 | 12 | 15 | 24 | 35 |
---|
Long-term debt | - | - | - | - | - | - | 17 | 47 | 38 | 37 | 29 |
---|
Deferred Revenue, Noncurrent | 4 | 5 | 6 | 6 | 6 | - | - | - | 16 | 15 | 14 |
---|
Operating Lease, Liability, Noncurrent | - | - | - | - | - | - | - | 3 | 2 | 2 | 6 |
---|
Other long-term liabilities | - | - | - | - | - | - | 1 | 3 | 2 | 2 | 1 |
---|
Total liabilities | 7 | 9 | 8 | 9 | 11 | 5 | 60 | 65 | 73 | 79 | 84 |
---|
Preferred Stock, Value, Issued | - | - | - | - | - | - | - | - | - | - | - |
---|
Common Stock, Value, Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
---|
Additional paid-in capital | - | - | - | 293 | 312 | 323 | 375 | 473 | 528 | 753 | 767 |
---|
Accumulated deficit | -252 | -264 | -277 | -271 | -292 | -311 | -364 | -465 | -511 | -569 | -671 |
---|
Accumulated other comprehensive income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
---|
Total stockholders’ equity | 14 | 8 | 15 | 23 | 21 | 13 | 12 | 8 | 19 | 184 | 96 |
---|
Total liabilities and stockholders’ equity | 21 | 16 | 23 | 32 | 32 | 19 | 72 | 73 | 92 | 263 | 180 |
---|